From garbage to garden - Recycling organic waste to contribute to a healthier planet
From garbage to garden - Recycling organic waste to contribute to a healthier planet
Search
Clinical Pharmacology
Boehringer Ingelheim is proud to offer a new two-year fellowship within Clinical Pharmacology. Click here to find out more.
Recognizing Parents Supporting Other Parents
Recognizing Parents Supporting Other Parents
Xochimilco
With its presence in Greece of more than a half century,
Shanghai
Shanghai serves as an important hub for all of the company’s three business areas: Human Pharma, Animal Health and Biopharmaceutical Contract Manufacturing.
Boehringer Ingelheim wins 2023 Prix Galien USA
Boehringer Ingelheim wins 2023 Prix Galien USA 2023 Prix Galien USA Best Orphan/Rare Disease Solution Award
African Swine Fever: Important Facts | Boehringer Ingelheim US
Click here to read more on the Boehringer Ingelheim efforts to understand and create a vaccine to prevent African Swine Fever in livestock across the globe.
Dan’s Unique Story
Each cancer journey is unique. In 2018 Dan was diagnosed with a rare form of sarcoma called dedifferentiated liposarcoma. Learn more about Dan’s unique approach to life with DDLPS.
A Unique Bond: human and animal health
A Unique Bond: human and animal health
A Few Ways We Support US Livestock | Boehringer Ingelheim US
Click here to view the Boehringer Ingelheim infographic on how we support livestock across the USA in partnership with the USDA's agriculture department.
Championing Novel Science
Championing Novel Science
Facing Lung Cancer: Keith’s Story
Facing Lung Cancer: Keith’s Story
Koropi
With its presence in Greece of more than a half century, Boehringer Ingelheim inaugurated the production facility in Koropi in 1975.
Scam alert
Scam alert
Sanofi and Boehringer Ingelheim confirm Closing of business swap on January 1st 2017
Sanofi and Boehringer Ingelheim confirm Closing of business swap on January 1st 2017
Cyltezo®, first and only FDA-approved Interchangeable biosimilar to Humira®, now commercially available in the U.S.
Cyltezo®, first and only FDA-approved Interchangeable biosimilar to Humira®, now commercially available in the U.S.
First half of 2021: Boehringer Ingelheim makes fundamental progress in research and development
First half of 2021: Boehringer Ingelheim makes fundamental progress in research and development
First half 2019: High levels of investment in R&D and robust organic growth
First half 2019: High levels of investment in R&D and robust organic growth
Why today’s depression trials demand smart new approaches
Why today’s depression trials demand smart new approaches
Protecting Humans & Animals | COVID-19 | Boehringer Ingelheim US
Read more on Boehringer Ingelheim's commitment to protecting both humans and animals during the COVID-19 pandemic.
Boehringer Ingelheim Animal Health Appoints Randolph Legg to Lead U.S. Commercial Business
Boehringer Ingelheim Animal Health Appoints Randolph Legg to Lead U.S. Commercial Business
Boehringer Ingelheim Animal Health Announces U.S. Leadership Transition
Boehringer Ingelheim Animal Health Announces U.S. Leadership Transition
BI Launches Vaccine to Protect Poultry | Boehringer Ingelheim US
Read more on the Boehringer Ingelheim launched Animal Health vaccine, aimed at protecting poultry from three different diseases.
Poultry vaccine site in Georgia continues to reduce carbon emissions
Going carbon neutral has resulted in measurable, positive impacts. From 2021 to 2022, the Gainesville site reduced its CO2 emissions by 23 percent – nearly 700 fewer tons of CO2 emissions are released into the atmosphere
Transition to renewable energy signals a broader commitment to environmental sustainability
Transition to renewable energy signals a broader commitment to environmental sustainability